BD Molecular Diagnostics

BD MAX™ System


Today’s laboratories face many challenges, including staff recruitment and retention, cost-containment pressures, increasing test volumes and diagnostic inaccuracies.


The BD MAX™ System is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours*. The BD MAX System is designed to help address today’s challenges, while preparing your laboratory for tomorrow’s possibilities.


Goal: Optimizing workflow to improve care

The BD MAX can:

  • Raise staff productivity through automation1
  • Leverage a versatile menu and streamlined workflow to reduce total cost2-4
  • Improve turnaround time for fast, appropriate treatment decisions2,3,5,6

Download the BD MAX efficiency benefits Info Sheet>>


Goal: Reaching more patients with the right tests at the right time

The BD MAX can:

  • Address complex patient needs through unique assay design
  • Tailor testing to manage variable workloads
  • Leverage a broad, expanding suite of molecular solutions

Download the BD MAX versatility benefits Info Sheet>>


Goal: Improving patient care with speed and accuracy

The BD MAX can:

  • Provide practitioners and patients accurate, timely results
  • Guide patient therapy, management and overall experience
  • Improve institutional, operational and financial outcomes

Download the BD MAX performance benefits Info Sheet>>


With the BD MAX System your laboratory can leverage a broad, expanding suite of molecular solutions. Looking to meet emerging diagnostic requirements and demands? Learn about BD MAX:

Visit BD Molecular Diagnostics for detailed information on the BD MAX System.

*Time to result for 24 samples tested with BD MAX™ Enteric Parasite Panel and BD MAX™ Extended Enteric Bacterial Panel is 4.5 hours and 3.5 hours, respectively.



  1. Knabl L et al. Comparison of the BD MAX Enteric Bacterial Panel assay with conventional diagnostic procedures in diarrheal stool samples. Eur J Clin Microbiol Infect Dis. 2016;35(1):131-136.
  2. Hirvonen JJ et al. Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs. Eur J Clin Microbiol Infect Dis. 2015;34(5):1005-1009.
  3. Bauman M. Transitioning from culture to molecular: implementation and integration of BD MAXTM Enteric Bacterial Panel at Cincinnati Children’s Hospital. BD Advertorial. Franklin Lakes, NJ: Becton, Dickinson and Company; 2015.
  4. Le Blanc L et al. Cost-effectiveness and laboratory workload efficiency of 8 C. difficile testing algorithms. Poster presented at: American Society for Microbiology; May 30–June 2, 2015; New Orleans, LA.
  5. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR Recomm Rep. 2014;63(RR-02):1-19.
  6. Powell S et al. The impact of molecular approaches to infectious disease diagnostics. Medical Laboratory Observer website. Updated August 2, 2015. Accessed May 15, 2017.

Request Information